Mechanisms of oxidative damage of low density lipoprotein in human atherosclerosis

Current Opinion in Lipidology

Volumn 8, Issue 5, 1997, Pages 268-274

  Heinecke, Jay W ^a  

^a Division of Atherosclerosis   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FREE RADICAL; HYPOCHLOROUS ACID; LIPOXYGENASE; LOW DENSITY LIPOPROTEIN; METAL ION; MYELOPEROXIDASE; NITROGEN;

ARTERY WALL; ATHEROSCLEROSIS; ENZYME ACTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIPID OXIDATION; LIPOPROTEIN METABOLISM; MASS SPECTROMETRY; OXIDATION; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW;

EID: 0030729868     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-199710000-00005     Document Type: Review

References (62)

1. Witztum JL, Steinberg D: Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest 1991, 88:1785-1792.
2. Stadtman ER: Protein oxidation and aging. Science 1992, 257:1220-1224.
3. Ames BN, Shigenaga MK, Hagen TM: Oxidants, antioxidants, and the degenerative diseases of aging. Proc Natl Acad Sci U S A 1993, 90:7915-7922.
4. Berliner JA, Heinecke JW: The role of oxidized lipoproteins in atherogenesis. Free Rad Biol Med 1996, 20:707-727.
5. Haberland ME, Cheng L, Fong D: Malondialdehyde-altered protein occurs in atheroma of Watanabe heritable hyperlipidemic rabbits. Science 1988, 241:215-218.
6. Rosenfeld ME, Palinski W, Yla-Herttuala S, Butler S, Witztum JL: Distribution of oxidation specific lipid-protein adducts and apolipoprotein-B in atherosclerotic lesions of varying severity from WHHL rabbits. Arterioscler 1990, 10:336-349.
7. Daugherty A, Zweifel BS, Sobel BE, Schonfeld G: Isolation of low density lipoprotein from atherosclerotic vascular tissue of Watanabe Heritable Hyperlipidemic rabbits. Arteriosclerosis 1988, 8:768-777.
8. Yla-Herttuala S, Palinski W, Rosenfeld ME, Parthasarathy S, Carew TE, Butler S, Witztum JL, Steinberg D: Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest 1989, 84:1086-1095.
9. Steinberg D: Clinical trials of antioxidants in atherosclerosis: are we doing the right thing? Lancet 1995, 346:36-38.
10. Jha P, Flather M, Lonn E, Farkouh M, Yusuf S: The antioxidant vitamins and cardiovascular disease - a critical review of epidemiologic and clinical trial data. Ann Intern Med 1995, 123:860-872.
11. Stephens NG, Parsons A, Schofield PM, Kelly F, Cheeseman K, Mitchinson MJ, Brown MJ: Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996, 347:781-786.
12. Heinecke JW, Rosen H, Chait A: Iron and copper promote modification of low density lipoprotein by human arterial smooth muscle cells in culture. J Clin Invest 1984, 74:1890-1894.
13. Morel DW, DiCorleto PE, Chisolm GM: Endothelial and smooth muscle cells alter low density lipoprotein in vitro by free radical oxidation. Arteriosclerosis 1984, 4:357-364.
14. Steinbrecher UP, Parthasarathy S, Leake DS, Witztum JL, Steinberg D: Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc Natl Acad Sci U S A 1984, 81:3883-3887.
15. Swain J, Gutteridge JMC: Prooxidant iron and copper, with ferroxidase and xanthine oxidase activity in human atherosclerotic material. FEBS Lett 1995, 368:513-515.
16. Lamb D, Mitchinson MJ, Leake DS: Transition metals within human atherosclerotic lesions can catalyze the oxidation of low density lipoprotein by macrophages. FEBS Lett 1995, 374:12-16.
17. Leeuwenburgh C, Rasmussen JE, Hsu FF, Mueller DM, Pennathur S, Heinecke JW: Mass spectrometric quantification of markers for protein oxidation by tyrosyl radical, copper, and hydroxyl radical in low density lipoprotein isolated from human atherosclerotic plaques. J Biol Chem 1997, 272:3520-3526. Stable isotope dilution gas chromatography-mass spectrometry is used to quantify the levels of o-tyrosine, m-tyrosine and o,o′-dityrosine in LDL oxidized in vitro, in LDL isolated from atherosclerotic lesions, and in aortic tissue at different stages of the atherosclerotic process.
18. Huggins TG, Wells-Knecht MC, Detorie NA, Baynes JW, Thorpe SR: Formation of O-tyrosine and dityrosine in proteins during radiolytic and metal-catalyzed oxidation. J Biol Chem 1993, 268:12341-2347.
19. Ascherio A, Willett WC: Are body iron stores related to the risk of coronary heart disease? N Engl J Med 1994, 330:1152-1154.
20. Bothwell TH, Charlton RW, Cook JD, Finch CA: Iron Metabolism in Man. Oxford: Blackwell Scientific Publishers; 1979.
21. Danks DM: Disorders of copper transport. In The Metabolic Basis of Inherited Disease, 6th edn. Edited by Scriver CR, Beaudet AL, Sly WS, Valley D. New York: McGraw-Hill, Inc.; 1989:1411-1422.
22. Yamamoto S: Mammalian lipoxygenases: molecular structures and functions. Biochem Biophys Acta 1992, 1128:117-131.
23. Sparrow CP, Parthasarathy S, Steinberg D: Enzymatic modification of LDL by purified lipoxygenase plus phospholiphase A2 mimics cell-mediated oxidative modification. J Lipid Res 1988, 29:745-753.
24. Parthasarathy S, Weiland E, Steinberg D: A role for endothelial cell lipoxygenase in the oxidative modification of low density lipoprotein. Proc Natl Acad Sci U S A 1989, 86:1046-1050.
25. Jessup W, Darley-Usmar V, O'Leary V, Bedwell OS: 5-Lipoxygenases is not essential for macrophage mediated oxidation of LDL. Biochem J 1991, 278:163-169.
26. Sparrow CP, Olszewski J: Cellular oxidative modification of LDL does not require lipoxygenases. Proc Natl Acad Sci U S A 1992, 89:128-131.
27. Benz DJ, Mol M, Ezaki M, Mori-Ito N, Zelan I, Miyanohara A, Friedmann T, Parthasarathy SA, Steinberg D, Witztum JL: Enhanced levels of lipoperoxides in low density lipoprotein incubated with fibroblasts expressing high levels of human 15-lipoxygenase. J Biol Chem 1995, 270:5191-5197.
28. Yla-Herttuala S, Rosenfeld ME, Parthasarathy S, Sigal E, Sarkioia T, Witztum JL, Steinberg D: Colocalization of 15-lipoxygenase mRNA and protein with epitopes of oxidized low density lipoprotein in macrophage-rich areas of atherosclerotic lesions. Proc Natl Acad Sci U S A 1987, 87:6959-6963.
29. Belkner J, Wiesner R, Rathman J, Barnett J, Sigal E, Kuhn H: Oxygenation of lipoproteins by mammalian lipoxygenases. Eur J Biochem 1993, 213:251-261.
30. Kuhn H, Heydeck D, Hugou I, Gniwotta C: In vivo action of 15-lipoxygenase in early stages of human atherosclerosis. J Clin Invest 1997, 99:888-893. Chiral phase HPLC is used to quantify the levels of 13S-HODE in LDL oxidized with lipoxygenase and copper, and in aortic tissue at different stages of the atherosclerotic process.
31. Folcik VA Nivar-Aristy RA, Krajewski LP, Cathcart MK: Lipoxygenase contributes to the oxidation of lipids in human atherosclerotic plaques. J Clin Invest 1996, 96:504-510. Chiral phase HPLC is used to quantify the levels of 13S-HODE in LDL oxidized with copper and in advanced atherosclerotic lesions.
32. Rao SI, Wilks A, Hamberg M, Ortiz de Montellano PR: The lipoxygenase activity of myoglobin. J Biol Chem 1994, 269:7210-7216.
33. Francis GA, Mendez AJ, Bierman EL, Heinecke JW: Oxidative tyrosylation of high density lipoprotein by peroxidase enhances cholesterol removal from cultured fibroblasts and macrophage foam cells. Proc Natl Acad Sci U S A 1993, 90:6631-6635.
34. Shen J, Herderick E, Cornhill JF, Zsigmond E, Kim H, Kuhn H, Guevara NV, Chan L: Macrophage-mediated 15-lipoxygenase expression protects against atherosclerosis development. J Clin Invest 1996, 98:2201-2208.
35. Klebanoff SF: Oxygen metabolism and the toxic properties of phagocytes. Ann Intern Med 1980, 93:480-489.
36. Maseri A: Inflammation, atherosclerosis, and ischemic events - exploring the hidden side of the moon. N Engl J Med 1997, 336:1014-1015. A review of the evidence that chronic inflammation is important in the pathogenesis of atherosclerosis.
37. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997, 336:973-979. Elevated levels of C-reactive protein, a marker of inflammation, are an important risk factor for cardiovascular disease in men.
38. Daugherty A, Rateri DL, Dunn JL, Heinecke JW: Myeloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest 1994, 94:437-444.
39. Hazell LJ, Arnold L, Flowers D, Waeg G, Malle E, Stocker R: Presence of hypochlorite-modified proteins in human atherosclerotic lesions. J Clin Invest 1996, 97:1535-1544.
40. Heinecke JW, Li W, Daehnke HL, Goldtein JA: Dityrosine, a specific marker of oxidation, is synthesized by the myeloperoxidase-hydrogen peroxide system of human neutrophils and macrophages. J Biol Chem 1993, 268:4069-4077.
41. Savenkova MI, Mueller DM, Heinecke JW: Tyrosyl radical generated by myeloperoxidase is a physiological catalyst for initiation of lipid peroxidation in low density lipoprotein. J Biol Chem 1994, 269:20394-20400.
42. Heinecke JW, Li W, Francis GA, Goldstein JA: Tyrosyl radical generated by myeloperoxidase catalyzes the oxidative cross-linking of proteins. J Clin Invest 1993, 91:2866-2872.
43. Harrison JE, Schultz J: Studies on the chlorinating activity of myeloperoxidase. J Biol Chem 1976, 251:1371-1374.
44. Foote CS, Goyne TE, Lehrer RI: Assessment of chlorination by human neutrophils. Nature 1981, 301:715-716.
45. Weiss SJ, Test ST, Eckmann CM, Ross D, Regiani S: Brominating oxidants generated by human eosinophils. Science 1986, 234:200-203.
46. Heinecke JW: Cellular mechanisms for the oxidative modification of lipoproteins: implications for atherogenesis. Coron Art Dis 1994, 5:205-210.
47. Thomas EL, Grisham MB, Jefferson MM: Preparation and characterization of chloramines. Meth Enzymol 1986, 132:569-585.
48. Domigan NM, Charlton TS, Duncan MW, Winterbourn CC, Kettle AJ: Chlorination of tyrosyl residues in peptides by myeloperoxidase and human neutrophils. J Biol Chem 1995, 270:16542-16548.
49. Kettle AJ: Neutrophils convert tyrosine residues in albumin to chlorotyrosine. FEBS Lett 1995, 379:103-106.
50. Hazen SL, Hsu FF, Mueller DM, Crowley JR, Heinecke JW: Human neutrophils employ chlorine gas as an oxidant during phagocytosis. J Clin Invest 1996, 98:1283-1289.
51. Hazen SL, Hsu FF, Mueller DM, Crowley JR, Heinecke JW: 3-Chlorotyrosine, a specific marker of myeloperoxidase-catalyzed oxidation, is markedly elevated in low density lipoprotein isolated from human atherosclerotic intima. J Clin Invest 1997, 99:2075-2081. Stable isotope dilution gas chromatography-mass spectrometry is used to quantify the levels of 3-chlorotyrosine in LDL oxidized in vitro, in LDL isolated from atherosclerotic lesions, and in advanced atherosclerotic lesions.
52. Moncada S, Palmer RM, Higgs EA: Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev 1991, 43:109-142.
53. Cooke JP, Tsao PS: Is NO an endogenous antiatherogenic molecule? Arterioscler Thromb 1994, 14:653.
54. Aji W, Ravalli S, Scabolcs M, Jiang X, Scianna RR, Michler RE, Cannon PJ: L-Arginine prevents xanthoma development and inhibits atherosclerosis in LDL receptor knock-out mice. Circulation 1997, 95:430-437.
55. Jessup W, Mohr D, Gieseg SP, Dean RT, Stocker R: The participation of nitric oxide in cell free and its restriction of macrophage-mediated oxidation of LDL. Biochem Biophys Acta 1992, 1180:72-82.
56. Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA: Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci U S A 1990, 87:1620-1624.
57. Graham AN, Hogg N, Kalyanaraman B, O'Leary V, Darley Usmar V, Moncade S: Peroxynitrite modifications of LDL leads to recognition by the macrophage scavenger receptor. FEBS 1993, 330:181-185.
58. Beckman JS, Chen J, Ischiropoulos H, Crow JP: Oxidative chemistry of peroxynitrite. Meth Enzymol 1994, 233:229-240.
59. Eiserich JP, Cross CE, Jones AD, Halliwell B, van der Vleit A: Formation of nitrating and chlorinating species by reaction of nitrite with hypochlorous acid: a novel mechanism for nitric oxide-mediated protein modification. J Biol Chem 1996, 271:19199-19208.
60. Beckmann JS, Ye YZ, Anderson PG, Chen J, Accavitti MA, Tarpey MM, White CR: Extensive nitration of protein tyrosines in human atherosclerosis detected by immunohistochemistry. Biol Chem Hoppe-Seyler 1994, 375:81-88.
61. Leeuwenburgh C, Hardy MM, Hazen SL, Wagner P, Oh-ishi S, Steinbrecher UP, Heinecke JW: Reactive nitrogen intermediates promote low density lipoprotein oxidation in human atherosclerosis. J Biol Chem 1997, 272:1433-1436. Stable isotope dilution gas chromatography-mass spectrometry is used to quantify the levels of 3-nitrotyrosine in LDL oxidized in vitro and in LDL isolated from atherosclerotic lesions.
62. Hazen SL, Hsu FF, Heinecke JW: p-Hydroxyphenylacetaldehyde is the major product of L-tyrosine oxidation by activated human phagocytes: a chloride-dependent mechanism for the conversion of free amino acids into reactive aldehydes by myeloperoxidase. J Biol Chem 1996, 271:1861-1867.